BDX Stock Forecast & Price Target

Becton Dickinson's robust performance is supported by significant positive volume growth projected in China, driven by volume-based procurement that will encompass approximately 80% of the portfolio by the end of 2026, further enhancing its position in the growing Biosurgery market. Additionally, the company has seen notable progress in its Alaris segment, achieving its strongest competitive wins since the 2023 relaunch, which has led to an increase in market share by around 100 basis points. Furthermore, BD Connected Care reported impressive sales of $1.13 billion, reflecting a year-over-year increase of 4.7% (excluding foreign exchange adjustments), indicating strong momentum in its product offerings.

Becton Dickinson's outlook appears negative due to several fundamental challenges, including a commitment to reduce leverage from approximately 3x to 2.5x, which may take 12-18 months, indicating potential liquidity constraints during this period. The company has also experienced declining revenue in key segments such as Alaris, compounded by tough year-over-year comparisons and ongoing market pressures in China, reduced lifesciences research funding, and diminished licensing revenue. Furthermore, the expectation of slow top-line growth, minor potential for meaningful EPS increases, and anticipated headwinds from business investments and tariffs raises concerns about the overall financial stability and shareholder returns at "new BD."